What do systematic reviews say?

5‐alpha reductase inhibitors vs placebo

5‐alpha reductase inhibitors showed no clear difference in adverse events compared with placebo (low certainty).

• Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome 2019 · Cochrane Headline outcomes only
  RR 0.87 [0.33, 2.3]
  2 studies · 105 participants
  Low

5‐alpha reductase inhibitors vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

5‐alpha reductase inhibitors vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

5‐alpha reductase inhibitors vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

5‐alpha reductase inhibitors vs placebo

• Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Moderate

5‐alpha reductase inhibitors vs placebo

5‐alpha reductase inhibitors showed no clear difference in prostatitis symptoms: 'responders' Number of participants with a 25%… compared with placebo (low certainty).

• Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome 2019 · Cochrane Headline outcomes only
  RR 2.13 [0.82, 5.53]
  1 study · 64 participants
  Low